Page 11234..10..»

Archive for the ‘Nano medicine’ Category

Global NANOTECHNOLOGY IN MEDICAL APPLICATIONS Statistics, CAGR, Outlook, and Covid-19 Impact 2016 The Bisouv Network – The Bisouv Network

Sunday, February 14th, 2021

Nanotechnology in Medical Applications: The Global Market

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.

Also Read:

Report Includes:

Also Read:

An overview of the global markets for nanotechnology used in medical applications

Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022

A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications

Also Read:

Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness

A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine

Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities

Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive marketSummary

Also Read:

Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.

The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.

Reasons for Doing the Study

Also Read:

Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.ABLYNX NV













































About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Contact Us:



Ph: +162-825-80070 (US)

Ph: +44 2035002763 (UK)

Here is the original post:
Global NANOTECHNOLOGY IN MEDICAL APPLICATIONS Statistics, CAGR, Outlook, and Covid-19 Impact 2016 The Bisouv Network - The Bisouv Network


Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The…

Sunday, February 14th, 2021

TheNanotechnology in Medical market outlooklooks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope and application of this report.

The report presents the market competitive landscape and a corresponding detailed analysis of the majorvendor/key playersin the market.Top Companiesin the Global Nanotechnology in Medical Market:Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune, Access, Camurus, Roche, Dentsply International, 3M, Celgene, Pfizer.

SPECIAL OFFER (Avail an Up-to 25% discount on this report, please fill the form and mention the code: MIR25 in the comments section)

Click the link to get a free Sample Copy of the Report@:

This report segments the global Nanotechnology in Medical market on the basis ofTypesare:

Nano Medicine

Nano Diagnosis


On the basis ofApplication, the Global Nanotechnology in Medical market is segmented into:




Investigator Observers Strong Growth in Specific Regions:

EuropeMarket (Germany, UK, France, Russia, Italy)

Center East and AfricaMarket (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

South AmericaMarket (Brazil, Argentina, Colombia)

North AmericaMarket (United States, Canada, Mexico)

Asia PacificMarket (China, Japan, Korea, India, Southeast Asia).

Inquire For Discount at:

Influence of the Nanotechnology in Medical market report:

-Comprehensive assessment of all opportunities and risk in the Nanotechnology in Medical market.

-Nanotechnology in Medical market recent innovations and major events

-Detailed study of business strategies for growth of the Nanotechnology in Medical market-leading players.

-Conclusive study about the growth plot of Nanotechnology in Medical market for forthcoming years.

-In-depth understanding of Nanotechnology in Medical market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Nanotechnology in Medical market.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth.

Finally, the Nanotechnology in Medical Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and market development rate and figure, and so on. Nanotechnology in Medical Industry report additionally Presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

About Us:

MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

MediaContact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687 |

See the article here:
Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The...


NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety…

Tuesday, February 9th, 2021

SHELTON, CT / ACCESSWIRE / February 8, 2021 / NanoViricides, Inc.. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based on a novel nanomedicines platform has announced today that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections was well tolerated in safety pharmacology studies required for progressing to human clinical trials.

The Company reports that its drug candidate NV-CoV-2 was found to be safe in the GLP safety pharmacology studies performed by an external contract research organization (CRO) in both rat and non-human primate (NHP) models. Additionally, multiple injections of NV-CoV-2 were also well tolerated in an extensive non-GLP study in rats that was performed by AR Biosystems, Inc., FL.

Based on the safety of NV-CoV-2 in these studies, the Company believes that projected dosages would be safe in human clinical trials. With these findings, the Company believes that it will be possible to administer repeated dosages of NV-CoV-2 in a human clinical trial, if needed, to achieve control over the coronavirus infection from SARS-CoV-2 or its variants.

In a GLP neuro-pulmonary safety pharmacology study in rats, the following conclusion was drawn: The intravenous administration of NV-CoV-2 at doses of 25, 50 and 100 mg/kg did not affect respiratory function in rats.

In a GLP cardiovascular function study in the NHP cynomolgus monkeys, the following conclusion was drawn: Intravenous infusion of NV-CoV-2 at 25, 37.5, and 50 mg/kg did not have any toxicologic effects on cardiac rhythm or ECG morphology in cynomolgus monkeys in this study. No significant effects on blood pressure and heart rate were observed after the intravenous infusion of NV-CoV-2.

These results were consistent with a more extensive, multiple injection non-GLP safety and tolerability study in Sprague-Dawley male and female rats. In this non-GLP study, NV-CoV-2 was injected intravenously (via tail vein) on each of days 0, 1, 2, 3, 4, and 5. Two different doses were used: 320mg/kg BW per injection, and 160 mg/kg BW per injection. Clinical observations, body weight, urine, blood chemistry, post-mortem findings, and organ histology were studied. In all parameters, NV-CoV-2 was well tolerated at both dosages throughout the study.

The Company has received draft reports from all of these studies. We anticipate receiving final audited reports on the GLP studies shortly.

The Company is preparing to submit a pre-IND application to the US FDA with safety tolerability and effectiveness data to obtain guidance regarding human clinical trials. Additionally, we are actively seeking opportunities to engage appropriate sites for human clinical trials. Further, we are engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA.

The need for the broad-spectrum, pan-coronavirus nanoviricide drug treatment cannot be overstated for combating the COVID-19 pandemic given the current circumstances and the present status of the pandemic. New virus variants continue to develop in the field. The variants that have advantages in terms of transmissibility, infectivity, and escape from drugs and vaccines will continue to evolve and spread, replacing prior variants. This is already well documented.

Several vaccines have been found to be substantially less effective in protecting against infection by the South African variant, N501Y-V.2 (also called lineage B.1.351) than the earlier variants. A mutation present in B.1.351 as well as Brazilian variant P.1 that is thought to be possibly linked to evasion from antibody drugs and vaccines, E484K, has also been reported in UK in a further differentiated mutant of the variant of concern lineage B.1.1.7. The available monoclonal antibody drugs and convalescent plasma antibodies have been reported to be less effective against several variants.

By the very nature of how they work, vaccines and antibodies tend to be highly specific to the target virus variant, and do not afford strong protection against differentiated variants that are evolutionary distant from the target variant. This scientific fact is now well demonstrated for the COVID-19 pandemic.

It is therefore clear that an effective broad-spectrum anti-coronavirus drug will be needed before the world can return to normal activity.

The Company previously had advanced NV-CoV-1 and had continued to work further with additional drug candidates. One of these drug candidates, namely, NV-CoV-2 was found to have several advantages over NV-CoV-1 in terms of manufacturability and dose formulation. Therefore the Company has advanced NV-CoV-2 into GLP safety/pharmacology studies.

NanoViricides is developing a broad-spectrum antiviral drug where the potential for escape of virus variants is minimized by the very design of the drug for the treatment of COVID-19 infected sick persons. In contrast, vaccines are not treatments for sick persons, and must be administered to healthy individuals, and further require several weeks for the recipient's immune system to become capable of protecting against the target virus strain which still may not protect against new virus variants circulating by that time.

NanoViricides has a strong advantage in that the Company has its own cGMP-capable manufacturing facility in Shelton, CT. This facility is capable of producing approximately 4kg of the COVID-19 drug per batch. We anticipate that this would be sufficient for human clinical trials, and possibly for initial introduction under Compassionate Use, Emergency Use Authorization or similar regulatory approval.

"We are pleased with the results of the safety pharmacology studies, and now we are confident that our COVID-19 drug candidate can advance into human clinical trials," said Anil R. Diwan, PhD, President and co-Founder of NanoViricides, Inc., and co-Inventor of its platform technologies and drug candidates.

About NanoViricides

NanoViricides, Inc. (the "Company")( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.

The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with remdesivir encapsulated in it. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines.


Public Relations Contact:MJ ClyburnTraDigital

SOURCE: NanoViricides, Inc.

View source version on

View post:
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety...


Nanorobots In Blood Market Top-Vendor And Industry Analysis By End-User Segments Till 2028 | Aries Chemical, GE Water & Process Technologies KSU…

Tuesday, February 9th, 2021

The Global Nanorobots In Blood Market Research Report Forecast 2021-2028 is a valuable source of insightful data for business strategists. It provides the Nanorobots In Blood industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Nanorobots In Blood market study provides comprehensive data which enhances the understanding, scope and application of this report.

Request a Free sample Copy of this premium

Key Players:

Nanorobots In Blood Market Segment by Solution Type, covers:

Nanorobots In Blood Market Segment by Application, covers:

Key Benefits

The report provides a qualitative and quantitative analysis of the current Nanorobots In Blood Market trends, forecasts, and market size from 2021 to 2028 to determine the prevailing opportunities. Porters Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry. Top impacting factors & major investment pockets are highlighted in the research. The major countries in each region are analysed and their revenue contribution is mentioned. The Nanorobots In Blood Market report also provides an understanding of the current position of the market players active in the small satellite industry.

The report begins with a brief introduction and Nanorobots In Blood market overview of the Nanorobots In Blood industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed, along with current trends and policies in the industry.

Request a discount on standard prices of this premium research

The report provides a detailed study of the growth rate of every segment with the help of charts and tables. Furthermore, various regions related to the growth of the market are analysed in the report.

Global Nanorobots In Blood Market: Regional Segment Analysis

Besides this, the research demonstrates the growth trends and upcoming opportunities in every region.

Analysts have revealed that the Nanorobots In Blood Market has shown several significant developments over the past few years. The report offers sound predictions on market value and volume that can be beneficial for the market players, investors, stakeholders, and new entrants to gain detailed insights and obtain a leading position in the market.

Additionally, the report offers an in-depth analysis of key market players functioning in the global Nanorobots In Blood industry.

Furthermore, it throws light on key business priorities in order to assist the companies. The global Nanorobots In Blood Market report summarized with different case studies from leading industries, policymakers, business owners, and industry experts. The growth predictions for numerous segments have been included in the report.

Reasons for Buying this Report:

Enquiry Before Buying

About QYReports:

We at QYReports, a leading market research report publisher cater to more than 4,000 prestigious clients worldwide meeting their customized research requirements in terms of market data size and its application. Our list of customers include renowned Chinese companys multinational companies, SMEs and private equity firms. Our business study covers a market size of over 30 industries offering you accurate, in depth and reliable market insight, industry analysis and structure. QYReports specialize in forecasts needed for investing in and execution of a new project globally and in Chinese markets.

Contact Us:

Name: Jones John

Contact number: +1-510-560-6005

204, Professional Center,

7950 NW 53rd Street, Miami, Florida 33166

Read this article:
Nanorobots In Blood Market Top-Vendor And Industry Analysis By End-User Segments Till 2028 | Aries Chemical, GE Water & Process Technologies KSU...


Precision NanoSystems Receives Contribution from the Government of Canada to Build RNA Medicine Biomanufacturing Centre – PRNewswire

Wednesday, February 3rd, 2021

"Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian companies advance made-in-Canada vaccines and therapies, while securing domestic manufacturing options for international vaccine candidates. This is all part of our government's commitment to protect the health and safety of all Canadians today, and in the future", said the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry.

PNI supports the development of genetic medicines by providing products and services to its clients worldwide who are creating new treatments for infectious diseases, rare diseases, cancer and other areas of unmet need. This project will help PNI establish a Biomanufacturing Centre that will expand Canada's epidemic and pandemic preparedness capacity and will enable PNI to expand its development and manufacturing services to support the clinical development and supply of new medicines.

"PNI's centre of manufacturing excellence of nanomedicine will be a state-of-the-art facility for the development and manufacture of genetic therapeutics and vaccines," James Taylor, CEO, Precision NanoSystems stated. "The centre will continue Canada's leadership in the creation of innovative solutions for the development and production of new medicines for the benefit of patients in Canada and beyond. This support from the Government of Canada helps PNI to further achieve our mission of accelerating the creation of transformative medicines that significantly impact human well-being."

About Precision NanoSystems Inc. (PNI)

PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine.PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

SOURCE Precision Nanosystems

View post:
Precision NanoSystems Receives Contribution from the Government of Canada to Build RNA Medicine Biomanufacturing Centre - PRNewswire


Vaccine Production in BC’s Future – AM 1150 (iHeartRadio)

Wednesday, February 3rd, 2021

As part of the federal governmentsinvestment in domestic vaccine capability, a Vancouver company is taking their $25.1 million allotment to build a massive manufacturing facility in the Lower Mainland.

South Vancouver-basedPrecision Nanosystemsis building a $50.2 million biomanufacturing centre that could produce up to 240 million doses of vaccine every year in the 40,000 square foot facility. It's still assessing possible locations.

Its estimated completion date is March 2023, but the companys CEO says the investment is important on a number of levels.

"It's an investment in pandemic preparedness, an investment in the future, an investment in these critical technologies that are really the technologies of the future, said James Taylor in a Zoom interview. What were focussed on is the medium- to long-term pandemic responsiveness as well as developing capabilities and capacity around genetic medicine itself, so our facility will be able to utilize for programs that are involved in cancer, infectious diseases, rare diseases.

The same kind of messenger RNA technology that companies like Pfizer-BioNTech and Moderna have developed to quickly create and manufacture their successful COVID-19 vaccines is the same idea behind many local companies like Precision Nanosystems. Many members of the scientific community believe such genetic medicines that treat diseases at the molecular level are on the cusp of revolutionizing medicine.

"As long as you know how to create those instructions -- that genetic code you need to convince your body to create that target -- you can design an mRNA vaccine against any antigen," said Nicole Basta, an associate professor of epidemiology at McGill told the Canadian Press.

Vancouver-based Acuitas Therapeutics developed a lipid nanoparticle to protect the delicate messenger RNA strands that can be broken down by the body.

Taylor described the Lower Mainland as a global hub in nano-medicines, pointing out the growing industry is deeply intertwined with researchers, scientists and experts working across borders on shared projects; Precision Nanosystems alone works with more than 160 other companies around the world.

This past a year has really shone a light on the importance of science and technology to solve deep problems globally, he said. It's important for us, as Canadians, to be strong participants in the development and innovation.

Read more from the original source:
Vaccine Production in BC's Future - AM 1150 (iHeartRadio)


New facility to be built in Vancouver will produce 240 million vaccine doses annually | Urbanized – Daily Hive

Wednesday, February 3rd, 2021

As the battle against COVID-19 rages on, Canada is ramping up its vaccine producing capabilities at home in an effort to fill in the gaping hole in national security made evident by the pandemic.

Vancouvers Precision NanoSystems Inc. (PNI) announced this week it received $25.1 million from the federal governments Strategic Innovation Fund to create its domestic vaccine biomanufacturing capability.

The federal contribution covers half of the total $50.2 million cost of the new biomanufacturing centre that will be built in Vancouver, focusing on the production of ribonucleic acid (RNA) lipid nanoparticle vaccines and genetic medicines.

But the first vaccines made in this 40,000-sq-ft facility will not be ready for immediate pandemic needs; the project is not expected to reach completion until 2023, however, it will help secure the national supplies for critical medicines, future COVID-19 vaccine needs, and vaccines for future pandemics.

When operational, it will have a capacity to manufacture up to 240 million doses of vaccine each year. The RNA vaccine technology it will use is also currently being utilized by Pfizer-BioNTech and Moderna to rapidly develop and produce their COVID-19 vaccines.

PNIs centre of manufacturing excellence of nanomedicine will be a state-of-the-art facility for the development and manufacture of genetic therapeutics and vaccines, saidJames Taylor, the CEO of Precision NanoSystems, in a statement.

The centre will continueCanadasleadership in the creation of innovative solutions for the development and production of new medicines for the benefit of patients inCanadaand beyond.

Prior to COVID-19, PNI was already seeing quick growth in its business of developing genetic medicines by offering products and services to help create new treatments for infectious diseases, rare diseases, cancers, and other ailments.

PNI announced two separate COVID-19 vaccine development partnerships in May 2020, including a DNA vaccine with Edmonton-basedEntos Pharmaceuticals.

That same month, another partnership was entered with Chinese vaccine companyCanSino Biologics, with PNI responsible for the development of the mRNA vaccine and CanSino Biologics responsible for the pre-clinical testing, human clinical trials, regulatory approval, and commercialization. The Chinese company has the rights to commercialize the vaccine product in Asia, except in Japan, with PNI retaining the rights for the rest of the world.

A report in the Globe and Mail last summer indicated the federal governments National Research Council ended its partnership with CanSino, after the Chinese government refused to ship a vaccine to Canada for trials.

In October 2020, the federal government also provided $18.2 million in funding for PNI to advance a COVID-19 mRNA vaccine candidate to clinical trials.

Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure thatCanadahas modern, flexible vaccine manufacturing capabilities now and in the future, saidFranois-Philippe Champagne, the federal Minister of Innovation, Science, and Industry, in a statement.

Our government is helping Canadian companies advance made-in-Canadavaccines and therapies, while securing domestic manufacturing options for international vaccine candidates.

The federal government is also funding new vaccine biomanufacturing facilities in Saskatchewan and Quebec.

Read the original:
New facility to be built in Vancouver will produce 240 million vaccine doses annually | Urbanized - Daily Hive


Faster tracking of treatment responses – MIT News

Wednesday, February 3rd, 2021

In the fight against severe diseases like cancer, patients often endure a discomforting, weekslong gap between when treatment begins and when doctors can tell if its working. The problem often stems from an inability to track the diseases progression in anything close to real time.

Now Glympse Bio, a startup spun out of the lab of Sangeeta Bhatia, the John J. and Dorothy Wilson Professor of Electrical Engineering and Computer Science at MIT and director of the Marble Center for Cancer Nanomedicine, is working to shine a light on disease activity using tiny synthetic biosensors. After being injected into the body, the sensors travel to the disease site and measure protein changes associated with that disease. The sensors are then excreted in urine and analyzed using standard laboratory techniques.

The company believes its technology holds potential to transform disease detection, tracking, and by providing clinicians with data-driven insights treatment.

When a patient is put on a medicine, its really a waiting game, says Bhatia, Glympse Bio co-founder who is also a member of MITs Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science. Theres often nothing to do but wait to see if a disease is responding. We hope this technology can provide information to clinicians and patients earlier.

Glympse recently completed a Phase 1 trial of its sensors in patients with non-alcoholic steatohepatitis (NASH), a potentially deadly liver disease estimated to affect about 12 percent of adults in the U.S. Because the current process for diagnosing NASH involves sampling a piece of the liver through a biopsy, it often remains undetected until the disease is in its most advanced stages.

Glympse is also tuning its sensors to track the progression of certain cancers, infections, and inflammation. Success in those fields would give drug development companies, doctors, and patients a potent new tool in the fight against an array of life-threatening diseases.

With this platform you open up several different universes, Glympse CEO Caroline Loew says. For diseases that are harder to diagnose, you get to diagnose them faster, you get to be able to develop drugs for them more effectively, and you get to treat them faster.

Sensing an opportunity

Like many great scientific advances, the discovery that led to Glympse was serendipitous. Around 2008, Bhatias group was using tagged magnetic particles that travel to tumors in the body, where they could reveal their location through an MRI scan. In every cancer experiment, the researchers noticed the bladder lit up with the tag.

We realized we didnt need an imaging machine anymore, we could just give a shot and do a urine test, Bhatia says.

By 2012, Glympse co-founder Gabe Kwong, a postdoc in Bhatias lab between 2009 and 2014, had developed the tagging technology enough to map changes in protein activity to the progression of multiple diseases. Some of that early work was funded, in part, by the Koch Institute Frontier Research Program.

After some encouragement from her colleagues, Bhatia assembled a team of advisors including Institute Professor Robert Langer and secured a grant from MITs Deshpande Center to start the company. Bhatia eventually took a sabbatical from MIT to help the company identify its first target, NASH, raise venture capital, secure a partnership with the pharmaceutical company Gilead Sciences, and understand how the sensors would be regulated by the Food and Drug Administration.

The progress was enough to attract Loew, who had spent her career helping large pharmaceutical companies develop drugs. Loew says she was impressed by the breadth of insights Glympse could glean with its biosensor platform, which measures the activity of enzymes called proteases that are altered in a variety of serious diseases.

Loew led the company as its focus has broadened from diagnostics to precise disease tracking during treatment.

We began thinking about earlier cancer detection because you can save a lot of lives by finding cancer early, Bhatia says. Now were realizing that we can potentially understand whether new drugs are working and if the patients are on the right medicine.

The company believes it can understand not just if a specific drug is working but how it is working through protease data.

We can help determine whether the drug is activating at a site of engagement, we can tell mechanisms of action because theres specific protease activity thats associated with that, we can determine through a course of treatment whether the disease is increasing or decreasing, we can track all that through a protease signature, Loew says.

A platform with potential

Through its partnership with Gilead, Glympses technology is expected to move into efficacy trials with NASH patients later this year. The company hopes those trials show the power of its approach for gathering previously unattainable data.

Those insights could also transform treatment. Looking forward, Glympse hopes to help clinicians make care decisions for patients based on both real-time disease response and how the disease has responded in similar patients at similar stages of treatment.

That would represent a paradigm shift in areas like cancer immunotherapy, in which doctors often must make do with little information for months after treatment begins.

Many of these patients have very fast advancing cancers, Loew says. To get the patients quickly stratified to the right treatment is critically important. Days mean everything to these patients, and sometimes we see patients waiting around for nine to 12 weeks to see if theyre having a response to these drugs. In our preclinical data, were determining if theres a response in a week or two. If were able to pull that through, its game-changing.

Read the original:
Faster tracking of treatment responses - MIT News


NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer – Business Wire

Wednesday, February 3rd, 2021

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standard of care. Expansion into esophageal cancer represents not only another step toward achieving our goals, it also highlights the ongoing progress of our clinical collaboration agreement with The University of Texas MD Anderson Cancer Center. Laurent Levy, CEO of Nanobiotix

NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the Company), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform the treatment of cancer, today announced that the first patient has been injected in a phase I study evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. The trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.

Background and Opportunity

According to the World Health Organization, esophageal cancer is currently the sixth most common cause of cancer death in the world and is estimated to have caused over 508,585 deaths in 2018. The American Cancer Society estimates that in 2020 in the United States, there were approximately 18,440 new esophageal cancer cases diagnosed, and approximately 16,170 deaths due to esophageal cancer. Approximately 20% of patients survive esophageal cancer at least five years after diagnosis.

Phase I Study of NBTXR3 Activated by Radiotherapy with Concurrent Chemotherapy for Patients with Esophageal Cancer (MD Anderson Study 2020-0122)

This study is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiotherapy with concurrent chemotherapy, and (ii) expansion at RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment-nave and radiographically non-metastatic at screening. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D of NBTXR3 activated by radiation therapy. Up to 24 subjects will be enrolled, including a maximum of 12 subjects for the dose-escalation part. Twelve additional subjects will be enrolled for the RP2D expansion part. Recruitment is ongoing and the planned enrollment period is 24 months.

Updates on this trial will be provided as they are made available by MD Anderson.



Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, potentially first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany


This press release contains certain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, anticipate, believe, expect, intend, on track, plan, scheduled, and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data, and our relationship with, and the performance of, our collaboration partners, and the funding of our operations. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However, these forward-looking statements are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020 under the caption Risk Factors and those set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Read the original post:
NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer - Business Wire


New Instrument Will Uncover Structure and Chemical Composition on Sub-Cell Scale – Georgia Tech News Center

Tuesday, January 12th, 2021

Science and Technology

January 11, 2021 Atlanta, GA

Click image to enlarge

Image shows a mass spectrometer and scanning electronic microscope that provide the foundation for the BeamMap system, which can simultaneously determine surface topology and chemical makeup of a biological sample.

A new imaging instrument able to simultaneously study both the surface of a biological sample and its chemical composition is the goal of a three-year, $1.2 million National Institutes of Health (NIH) research award. Combining information from analysis of the chemical composition and physical structure of the surface of cells, tissues and even individual biomolecules inside the cells could provide a new way to study tumor growth, disease progression, cell function, and other key issues.

The technology being developed, termed Beam Enabled Accurate Mapping & Molecular Analyte Profiling (BeamMap), combines data from scanning electron microscopy and a new mode of desorption electrospray ionization mass spectrometry (DESI-MS) to simultaneously determine surface topology and chemical makeup. BeamMap uses an electron beam and a focused nanospray of electrified liquid to gather the two types of information, which is correlated with help of image processing software. The research is funded by the National Institute of Healths National Institute of General Medical Sciences (NIGMS).

To make this breakthrough tool, we need to be able to provide both topological and chemical information at resolutions on the scale of micrometers and sub-micrometers to be able to discover molecular makeup and biological function at a sub-cellular level, said Andrei Fedorov, Professor and Rae S. and Frank H. Neely Chair in the George W. Woodruff School of Mechanical Engineering at the Georgia Institute of Technology. This will require simultaneous advances, and we will be pushing the limits of both imaging tools and what mass spectrometers can do.

Because of the use of mass spectrometry for molecular sensing, BeamMap will be able to characterize proteins, metabolites, and lipid chemistry without requiring an a priori knowledge of what chemical species are present. With its ability to correlate chemical information with topological information acquired with focused electron and ion-spray beams in vacuum, the new instrument is expected to provide an order of magnitude improvement in the resolution of electrospray-based techniques, with chemical imaging resolution of approximately 250 nanometers and electron microscopy topological resolution of about 50 nanometers. BeamMap should be useful in fundamental and clinical biology, medicine, analytical chemistry, and bioengineering.

Processes that are currently invisible to us could actually be seen using BeamMap, so we will have evidence for things we can only speculate about now, Fedorov said. Being able to see what is happening at the subcellular level will allow us to get a better understanding of how biological systems behave. That will allow us to create hypotheses for how cells and tissues interact with the environment, potentially leading to a whole host of new therapeutic applications.

Among the major challenges that require an innovative research approach are the creation of soft ionization and highly local sample extraction necessary for keeping the biomolecules intact and the ability to effectively deliver the charged molecules to the vacuum environment of the mass spectrometer, he said.

We will need to fine-tune the energy of the beam that sprays on the substrate to provide the resolution we need, Fedorov said. We need to extract live biomolecules and ionize them without disrupting their structure. To do this, we will have to use the softest possible ionization.

The instrument will use the electrospray technique to create charged molecules of solvent focused in a beam about 100 nanometers in diameter. As the beam of charged solvent molecules hits the surface of the biological sample, it will ablate molecules from samples surface and move them into the surrounding vacuum environment of the SEM imaging chamber. The molecules will be charged and volatilized by the impinging nano-electrospray at a precisely tuned energy input, and then be extracted for immediate analysis in the mass spectrometer.

In parallel, an electron beam that can be focused down to 10 nanometers will be scanning and profiling the structures and features of the surfaces from which the molecules are being extracted by the electrospray. Correlating data from the two beams will provide information about the chemical makeup of the cell surface, the organelles and intracellular structures being imaged topologically.

Using multiple passes of the two beams will allow removal of layers from the samples, allowing internal structures to be mapped. Fedorov said producing each image will require several minutes, the timing limited by the speed at which the samples can be moved into the mass spectrometer and analyzed.

The characterization will be done in an electron microscope vacuum chamber, with the samples on a stage that can be moved in three dimensions. The stage will also provide cooling and hydration for the living samples during the imaging process.

The idea for the instrument came from a discussion with Andrs Garca, Regents' Professor in the George Woodruff School of Mechanical Engineering and executive director of Georgia Techs Institute for Bioengineering and Bioscience. Garca studies pancreatic cells as part of research into diabetes, and plans to use information from the new technique to develop a better understanding of the disease.

BeamMap is an exciting technological advance that will provide unparalleled biological and chemical information with high spatial resolution to analyze complex biological processes, Garca said. We are very much looking forward to applying it to understand diabetes disease progression.

This research was supported by Award 1R01GM138802-01 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NIH.

Research NewsGeorgia Institute of Technology177 North AvenueAtlanta, Georgia 30332-0181 USA

Media Relations Contact: John Toon (404-894-6986) (

Writer: John Toon

See the original post here:
New Instrument Will Uncover Structure and Chemical Composition on Sub-Cell Scale - Georgia Tech News Center


Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution – The Hub at Johns Hopkins

Saturday, January 9th, 2021

ByHub staff report

Philanthropist and Johns Hopkins Medicine trustee David M. Rubenstein has made a $15 million commitment to the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins to support the department's research.

Image caption: David M. Rubenstein

The gift, his second pledge of that size to the department, will establish the David M. Rubenstein Precision Medicine Center of Excellence and will deepen his support for basic science researchers focused on the development of therapeutic approaches to preserve and restore hearing. Three strategic project teams, working in collaboration with researchers across Johns Hopkins University, will explore inner ear hair cell repair, sensory neuron repair, and nanomedicine drugs and drug delivery.

Rubenstein's gift will also support core facilities for these teams, consisting of:

Additionally, funds from this gift will support an annual conference and a speaker series.

"David's initial gift has helped Johns Hopkins researchers make important discoveries in several crucial areas related to hearing and hearing loss," said Paul B. Rothman, dean of the School of Medicine and CEO of Johns Hopkins Medicine. "But there is so much more to be done in this area, and once again, David has stepped forward. We are grateful for all that his generosity has made possible so far, and we are even more excited about what this new commitment will allow us to accomplish going forward. In the end, this work will help the millions of people who struggle every day with hearing problems."

Rubenstein's earlier gift to the department, made in 2015, funded the creation of an endowment to support cross-institutional accelerator grants. Any researcher at Johns Hopkins may apply for a grant for new or existing research to further the understanding of hearing. Grant amounts vary. In FY19, a total of $800,000 was awarded to seven different research projects, plus research core support. The earlier gift also established an endowed professorship, providing critical funds in perpetuity to support a leading faculty member in research and teaching.

"David's support has enabled innovative research projects that leverage the expertise and imagination of scientists, engineers, and clinicians from across Johns Hopkins," said Paul Fuchs, the inaugural David M. Rubenstein Research Professor of OtolaryngologyHead and Neck Surgery. "This is particularly important as we move from basic discovery of molecular and cellular mechanisms, to targeting these for therapeutic benefit. Current efforts employ gene therapy to correct inherited deafness, to regenerate cochlear hair cells, or to enhance protection from acoustic trauma. Other strategies aim to re-establish lost connections from inner ear to brain, a significant contributor to noise-induced and age-related hearing loss."

To learn more about some of the advances made possible through Rubenstein's generosity and hear from the researchers, visit the Otolaryngology-Head and Neck Surgery YouTube playlist.

Rubenstein is a founder and co-executive chairman of The Carlyle Group, a global investment firm. Rubenstein is a noted philanthropist and a long-time member of the Johns Hopkins Medicine board of trustees.

"It is a privilege to support the talented and committed researchers and doctors of Johns Hopkins who are helping people suffering from hearing loss," Rubenstein said. "I am impressed with the progress made in recent years and hope this new gift will accelerate and deepen those efforts."

Read the original:
Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution - The Hub at Johns Hopkins


COVID-19 Impact on Nanomedicine Market Size, Latest Trends, Growth and Share 2020 to 2026| Clinical Cardiology, Urology, Genetics, Orthopedics -…

Saturday, January 9th, 2021

United States of America:-The Nanomedicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Nanomedicine market size is expected to gain market growth in the forecast period of 2020 to 2026, with a CAGR of xx% in the forecast period of 2020 to 2026 and will expected to reach USD xx million by 2026, from USD xx million in 2019.

Under COVID-19 Outbreak, how the Nanomedicine Industry will develop is also analyzed in detail in COVID Impact Chapter of this report.

For Better Understanding, Download FREE Sample Copy of Nanomedicine Market Report(Including full TOC, Graphs, Sample Data, and Tables)@

Some of top players influencing the Global Nanomedicine market:

Clinical Cardiology, Urology, Genetics, Orthopedics, Ophthalmology

Note: We can provide market report in regional language too, German/French/Japanese. We have researched the situation of COVID-19 thoroughly and Our new sample has been updated to reflect COVID-19 Impact on industry trends. We also offer a 25% discount.

Market segmentation

Nanomedicine market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Majortype, primarily split into

Pharmaceuticals and Healthcare

Major applications/end users, including

Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends.):

This report examines all the key factors influencing growth of global Nanomedicine market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Nanomedicine market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

The Nanomedicine market is analysed and market size information is provided by regions (countries).

The key regions covered in the Nanomedicine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Nanomedicine market presented in the report. This section sheds light on the sales growth of different regional and country-level Nanomedicine markets. For the historical and forecast period 2015 to 2026, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Nanomedicine market.

Get Table of Content, Tables, and Figures of Nanomedicine Market Report:

Some of the key questions answered in this report:

What will the market growth rate, growth momentum or acceleration market carries during the forecast period?Which are the key factors driving the Nanomedicine market?What was the size of the emerging Nanomedicine market by value in 2020?What will be the size of the emerging Nanomedicine market in 2026?Which region is expected to hold the highest market share in the Nanomedicine market?What trends, challenges and barriers will impact the development and sizing of the Global Nanomedicine market?What is sales volume, revenue, and price analysis of top manufacturers of Nanomedicine market?What are the Nanomedicine market opportunities and threats faced by the vendors in the global Nanomedicine Industry?

The reports conclusion leads into the overall scope of the Global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the Global Nanomedicine market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email [emailprotected]Web:-

COVID-19 Impact on Nanomedicine Market Size, Latest Trends, Growth and Share 2020 to 2026| Clinical Cardiology, Urology, Genetics, Orthopedics -...


Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – LionLowdown

Saturday, January 9th, 2021

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.


The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.


Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.


Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at:

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage


Email: [emailprotected]

Contact: +919607065656/ +919607195908

See more here:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - LionLowdown


Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide…

Wednesday, December 16th, 2020

SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.

As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.

Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.

The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (

About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.

About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit

Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646)

Investor ContactBruce MackleLifeSci Advisors, LLC(929)

See original here:
Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide...


Global Nanomedicine market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -…

Wednesday, December 16th, 2020

Global Nanomedicine market Industry Trends and Forecast to 2027 New Research Report Added to database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it. To build an influential report, detailed market analysis has been conducted with the inputs from industry experts. By working on a number of steps for collecting and analysing market data, this supreme market research report is prepared with the expert team. It describes various definitions and segmentation or classifications of the industry, applications of the industry and value chain structure. Businesses can obtain a complete knowhow of general market conditions and tendencies with the information and data involved in the credible Global Nanomedicine market business report. The foremost areas of market analysis such as market definition, market segmentation, competitive analysis and research methodology are looked upon very vigilantly and precisely throughout the report.

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global nanomedicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

To comprehend Global Nanomedicine market dynamics in the world mainly, the worldwide Nanomedicine market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


See the original post here:
Global Nanomedicine market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -...


NHMRC awards Griffith University $4.5 million in research funding – Griffith News

Wednesday, December 16th, 2020

Key Griffith University research projects have received $4.5 million in funding from the National Health and Medical Research Council.

Announced on December 15 by the Federal Minister for Health, The Honorable Greg Hunt MP, the seven Ideas Grants projects will contribute to vital health and medical research.

Deputy Vice Chancellor (Research) Professor Mario Pinto said the funding highlights the extraordinary work conducted by the Universitys researchers in addressing major societal health challenges.

These projects have the potential to make a significant difference to peoples health and wellbeing. I extend my congratulations and appreciation to all staff who have contributed to these efforts.

More than half the funding for Griffith University was awarded to projects within theInstitute for Glycomics, withfour research projects securing $2.56 million to explore a super vaccine that tackles bothinfluenza virus andGroup A Streptococcus bacteria and other vaccine development projects that tackle other clinically important bacterial infections.

Institute Director Professor Mark von Itzstein AO said the awards cemented the Institutes reputation as a leading biomedical research institute.

Our institute is focussed on translational research outcomes that diagnose, prevent and treat diseases of global impact. These grants will significantly assist our researchers to deliver on our mission to achieve a disease-free world.


Dr Mehfuz Zaman, Professor Mark von Itzstein and Professor Michael Good (Institute for Glycomics) awarded $707, 717 for the project Vaccine to prevent Influenza Virus and Bacterial superinfection (Associate Professor Victor Huber, University of South Dakota).

Associate Professor Kate Seib, Professor Michael Jennings and Dr Arun Everest-Dass (Institute for Glycomics) awarded $826,490 for the project Gonococcal vaccine development guided by a cross-protective meningococcal vaccine (Dr Caroline Thng, Gold Coast Health).

Dr Freda Jen, Associate Professor Kate Seib, Professor Michael Jennings and Dr Milton Kiefel (Institute for Glycomics) awarded $526,949.6 for the project Targeting a bacterial glycol-Achilles heel to make new vaccines for Haemophilus influenzae and Neisseria gonorrhoeae.

Professor Michael Jennings, Associate Professor Thomas Haselhorst, Dr Lucy Shewell, Dr Christopher Day (Institute for Glycomics) awarded $608,425 for the project Structure and biophysical analysis aided design of novel toxoid vaccines for a major class of bacterial toxins (Prof James Paton, The University of Adelaide, Prof Mark Walker, The University of Queensland and Prof Victor Torres, New York University).

Dr David Lloyd, Dr Claudio Pizzolato, Dr David Saxby and Dr Laura Diamond (Menzies Health Institute Queensland) awarded $860, 231 for the project Osteoarthritis compass: Predicting personalized disease onset and progression with future capacity for clinical use (Dr Michelle Hall, Assoc Prof Adam Bryant University of Melbourne, Prof David Hunter, University of Sydney; Prof Juha Toyras, Dr Shekhar Chandra, Assoc Prof Craig Engstrom The University of Queensland; Dr Jurgen Fripp, CSIRO Australian e-Health Research Centre; Prof Rami Korhonen, University of Eastern Finland).

Professor Heidi Zeeman, Dr David Painter and Professor Elizabeth Kendall (Menzies Health Institute Queensland) awarded $513, 483 for the project Dimensional Attention Modelling for Neglect Detection (DIAMOND): A novel application for brain injury (Prof Julie Bernhardt, Florey Institute of Neuroscience and Mental Health).

Associate Professor Hang Ta (Queensland Micro and Nanotechnology Centre/GRIDD) awarded $523, 342 for the project Developing smart nanomedicine to enable advanced diagnosis and stimuli-responsive treatment for atherosclerosis and thrombosis (Dr Nghia Truong Phuoc, Monash University; Dr Gary Cowin, Dr Nyoman Kurniawan, Prof Zhiping Xu, The University of Queensland and Prof Karlheinz Peter, Baker Heart and Diabetes Institute).

Griffith researchers involved in research led by other institutions


Prof Randipsingh Bindra, Dr Mo Chen, Assoc Prof James St John, Assoc Prof Jenny Ekberg, Dr Brent McMonagle (Griffith Health) are part of a team led by Assoc Prof Jeremy Crook (University of Wollongong) awarded $805,064.45 for the project titled A wireless electric nerve-guide for peripheral nerve repair (Dr Eva Tomaskovic-Crook, University of Wollongong).

Assoc Prof Joshua Byrnes (MHIQ, Health) is part of a team led by Assoc Prof Maree Toombs (The University of Queensland) awarded $1,279,602.45 for the project titled Advancing equitable and non-discriminatory access to health services for First Nations peoples: A multidisciplinary Queensland Human Rights Act case study (Dr Shivashankar Hiriyur Nagaraj, Queensland University of Technology; Jodie Luck, Mr DanielWilliamson, Queensland Health; Mr Jed Fraser, Queensland Aboriginal and Islander Health Council; Prof Anthony Smith, Dr Claire Brolan Dr Caitlin Curtis, Dr Sandra Creamer, Prof Wendy Hoy, Dr Amelia Radke (The University of Queensland), Dr Kelly Dingli (Queensland Aboriginal and Islander Health Council); Mr Gregory Pratt (The Council of the Queensland Institute of Medical Research)

ARC Linkage 2020 Round 1

Dr Pooja Sawrikar (School of Human Services and Social Work) is part of a Western Sydney University project led by Assoc Prof Rebekah Grace awarded $387,107 for the project Upholding the right to cultural connection for children in care.

NHMRC awards Griffith University $4.5 million in research funding - Griffith News


Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection – -…

Thursday, December 10th, 2020

DUBLIN--(BUSINESS WIRE)--The "Nanomedicine Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has been added to's offering.

This report describes the global market size of Nanomedicine from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025. For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.

For the competitor segment, the report includes global key players of Nanomedicine as well as some small players.

The information for each competitor includes:

Applications Segment:

Companies Covered:

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Abbreviation and Acronyms

Chapter 3 Preface

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter 4 Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End-users

Chapter 5 Market Trend Analysis

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

Chapter 6 Industry Chain Analysis

6.1 Upstream/Suppliers Analysis

6.2 Nanomedicine Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End-users

Chapter 7 Latest Market Dynamics

7.1 Latest News

7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

Chapter 8 Trading Analysis

8.1 Export of Nanomedicine by Region

8.2 Import of Nanomedicine by Region

8.3 Balance of Trade

Chapter 9 Historical and Forecast Nanomedicine Market in North America (2015-2025)

9.1 Nanomedicine Market Size

9.2 Nanomedicine Demand by End Use

9.3 Competition by Players/Suppliers

9.4 Type Segmentation and Price

9.5 Key Countries Analysis

9.5.1 US

9.5.2 Canada

9.5.3 Mexico

Chapter 10 Historical and Forecast Nanomedicine Market in South America (2015-2025)

10.1 Nanomedicine Market Size

10.2 Nanomedicine Demand by End Use

10.3 Competition by Players/Suppliers

10.4 Type Segmentation and Price

10.5 Key Countries Analysis

10.5.1 Brazil

10.5.2 Argentina

10.5.3 Chile

10.5.4 Peru

Chapter 11 Historical and Forecast Nanomedicine Market in Asia & Pacific (2015-2025)

11.1 Nanomedicine Market Size

11.2 Nanomedicine Demand by End Use

11.3 Competition by Players/Suppliers

11.4 Type Segmentation and Price

11.5 Key Countries Analysis

11.5.1 China

11.5.2 India

11.5.3 Japan

11.5.4 South Korea

11.5.5 Asean

11.5.6 Australia

Chapter 12 Historical and Forecast Nanomedicine Market in Europe (2015-2025)

12.1 Nanomedicine Market Size

12.2 Nanomedicine Demand by End Use

12.3 Competition by Players/Suppliers

12.4 Type Segmentation and Price

12.5 Key Countries Analysis

12.5.1 Germany

12.5.2 France

12.5.3 UK

12.5.4 Italy

12.5.5 Spain

12.5.6 Belgium

12.5.7 Netherlands

12.5.8 Austria

12.5.9 Poland

12.5.10 Russia

Chapter 13 Historical and Forecast Nanomedicine Market in MEA (2015-2025)

13.1 Nanomedicine Market Size

13.2 Nanomedicine Demand by End Use

13.3 Competition by Players/Suppliers

13.4 Type Segmentation and Price

13.5 Key Countries Analysis

13.5.1 Egypt

13.5.2 Israel

13.5.3 South Africa

13.5.4 Gcc

13.5.5 Turkey

Chapter 14 Summary for Global Nanomedicine Market (2015-2020)

Continue reading here:
Global Nanomedicine Market Analysis and Forecast to 2025 by Cancer Detection, Monitoring Therapy & Disease Detection - -...


Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market – BioSpace

Thursday, December 10th, 2020

Medical Physics Market: Overview

Medical physics has transformed practice of diagnostic and therapeutic medicine, which relates to the use of radiation in medicine. The role of medical physicists in ensuring quality radiation therapy, improving the performance of quality medical imaging is a key factor underpinning the evolution of the medical physics market.

Research in medical physics has focused on assessing the potentially harmful effects of radiation on patients, clinicians, and healthcare staff. Strides that diagnostic and therapeutic medicine has made over the past few years have shaped the growth trajectory of the overall medical physics market. The expanding role of radiology, radiotherapy, and nuclear medicine in diagnostics and therapeutics is a case in point.

Over the years, physicists have been increasingly leaning on discovering processes, procedures, and technologies, that will expand the scope and relevance of healthcare applications. These efforts reinforce the growing outlook of the medical physics market.

Request Brochure of Report -

Medical Physics Market: Competitive Analysis and Key Developments

In recent years, medical physicists are being exhorted to improve their contribution to healthcare systems world over. A number of frameworks supporting related strategies is key to offering momentum in this direction. The American Association of Physicists in Medicine (AAPM ) in 2018 devised such a framework Medical Physics 3.0 (MP 3.0) after two years of relentless deliberations to this end. This will help greatly reinvigorate the role of medical physics in patient care in general, expanding the horizon of the market.

The association has urged physicists to securitize their role in medical area, and eventually gain a comprehensive understanding of patient care. Such initiatives are helpful in boosting the prospects of the medical physics market. Experts believe that Medical Physics 3.0 (MP3.0) is likely to set the pace for sustainable excellence in medical physics, my maximizing the contribution of physicists to improvement of human health.

Over the past few years, the medical physics market has been replete with mergers and acquisitions among the healthcare system manufacturers and healthcare providers. This has helped in boosting the adoption of cutting-edge diagnostic imaging in the medical physics market.

Request for Analysis of COVID-19 Impact on Medical Physics Market -

Medical Physics Market: Key Trends

Medical physicists have been instrumental in improving the clinical efficacy and safety of wide spectrum of diagnostic and therapeutic modality. These include mammography systems, X-ray systems, computed tomography, magnetic resonance imaging, SPECT, and PET. Key end users include hospitals, academic and research institutes, ambulatory surgery centers, and diagnostic imaging centers.

The need for reducing radiation toxicity in tomotherapy and intensity modulation radiotherapy (IMRT) is boosting the medical physics market. Medical physics is a mix of scientists and healthcare and medical professional. Thus, their role in transforming human and animal health has expanded the vistas in medical physics market.

Request for Custom Research -

In coming years, future slew of investments in the medical physics market include orthopedics, ophthalmology, medical photonics, surgery, radiogenomics, nano?medicine, dentistry, vascular medicine, and neuro?science.

Medical Physics Market: Regional Analysis

On the regional front, North America and Europe have been vastly attractive medical physics markets. These regional markets have seen the increasing trend of outsourcing of medical physics. In recent years, the role of numerous regional associations, notably in the U.S., in expanding the role of medical physicists in human health has cemented the revenue potential of the global medical physics market. Strides being made by nuclear medicine have spurred revenues in the North America medical physics market.

Pre Book Medical Physics Market Report at

The growing incidence of chronic diseases in developing regions such as Asia Pacific and Latin America is opening promising investment scope in these, making them fast emerging markets.

Browse More Trending by Transparency Market Research:

Injectable Benzodiazepine Market:

Oncology Small Molecule Drugs Market:

Protein A Resin Market:

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

ContactTransparency Market Research,90 State Street, Suite 700,Albany, NY 12207Tel: +1-518-618-1030USA - Canada Toll Free: 866-552-3453Website:

See the original post:
Medical Physics Market: Growing Incidence of Chronic Diseases in Developing Regions to Drive the Market - BioSpace


Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish – Stanford University News

Thursday, December 10th, 2020

by Crista Leigh Farrell on December 4, 2020 4:24 pm

JOSEPH DESIMONE, the Sanjiv Sam Gambhir Professor in Translational Medicine and professor of chemical engineering, has been named the recipient of the 2019-20 Harvey Prize in science and technology in recognition of contributions in materials science, chemistry, polymer science and technology, nanomedicine, and 3D printing.

Joseph DeSimone

The Harvey Prize, the highest honor of the Technion-Israel Institute of Technology, recognizes breakthroughs in research that benefit humanity. The prize administrators said DeSimones work is a model for combining basic scientific discoveries with developments of industrial technologies that have a significant influence.

It is incredibly humbling to be selected for the Harvey Prize, said DeSimone. I have been fortunate in my career to work with brilliant students and colleagues to make advances in science and technology toward improving the human condition, and this is a tremendous honor and testament to our work together.

DeSimone, who joined the Stanford faculty in September, holds faculty appointments in the Department of Radiology, the Department of Chemical Engineering and, by courtesy, the Graduate School of Business. He previously held a joint appointment in chemistry and chemical engineering at the University of North Carolina at Chapel Hill and North Carolina State University.

An author of more than 350 scientific articles and an inventor on more than 200 issued patents, DeSimone is known for advances rooted in polymer science that have spawned new technologies and areas of research, as well as for translating discoveries made in his laboratory to the marketplace.

In the 1990s, he and students invented an environmentally friendly process for synthesizing high-performance plastics without the use of hazardous solvents. In 2004, DeSimone and his team invented a breakthrough nanoparticle fabrication process, leading to the launch of multiple medical products in clinical trials. In 2015, he and colleagues reported a breakthrough advance in polymer 3D printing, which led DeSimone to co-found Carbon, a company whose technology has enabled cutting-edge products in such industries as footwear, dental, medical, automotive and aerospace.

DeSimone is one of only 25 people elected to all three branches of the U.S. national academies (Sciences, Engineering and Medicine). In 2016, President Obama presented him with the National Medal of Technology and Innovation.

DeSimone joins other Stanford faculty members as a winner of the Harvey Prize, including RICHARD ZARE, DONALD KNUTH, ROGER KORNBERG, KARL DEISSEROTH and CARLA SHATZ.

DeSimone will receive the prize at the Technion in Haifa, Israel, in June if pandemic conditions permit.

Follow this link:
Joseph DeSimone wins Harvey Prize in Science and Technology | The Dish - Stanford University News


Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 –

Friday, December 4th, 2020

A new research document is added in DBMR database of 350 pages, titled as Global Cancer Nanomedicine Market Size, Share, Growth, Trends, Industry By Type (Inorganic Nanoparticles, Organic Nanoparticles), Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents), Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems), Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others), Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI)), Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III) Country and Forecast with detailed analysis, Competitive landscape, forecast and strategies. Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Alnylam Pharmaceuticals, Inc., Amgen Foundation, Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca, Cadila Pharmaceuticals, etc. The study conducted for Cancer Nanomedicine industry also analyses the market status, size, share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, and distributors with the help of SWOT analysis and Porters Five Forces Analysis.

Download Free Sample (350 Pages PDF, Full TOC, List of Tables & Figures, and Chart) Report @

Data Bridge Market Research analyses the Cancer Nanomedicine Market to grow at a CAGR of 12.50% in the forecast period. The growing usages of nanomedicine in drug delivery technology will further create various opportunities for the growth of the market.

The Cancer Nanomedicine Market report encompasses the general idea of the global Cancer Nanomedicine market including definition, classifications, and applications. Further, it includes the all-inclusive comprehension of several factors such as drivers, constraints, and major micro markets. The report is a wide-ranging source of widespread facts and figures for business strategists as it offers the historical &futuristic data such as demand & supply data, cost, revenue, profit, supply chain value, and so on. Furthermore, it entails the key market features, comprising production, revenue, price, capacity, gross margin, market share, consumption, gross, production rate, demand/supply, cost, capacity utilization rate, export/import, and CAGR (compound annual growth rate). In addition the report encompasses global Cancer Nanomedicine market segmentation on the basis of diverse facets like product/service type, application, technology, end-users, and major geographic regions North America, Europe, Asia-Pacific and Latin America. Apart from this, the researcher market analyst and experts present their outlook or insights of product sales, market share, and value along with the possible opportunities to grow or tap into in these regions.


Surging volume of patients suffering from cancer, and other chronic disorders, increasing number of geriatric population across the globe, increasing development of nanotechnology-based drugs as well as therapies, adoption of advanced technologies are some of the factors which will likely to enhance the growth of the cancer nanomedicine market in the forecast period of 2020-2027. On the other hand, surging levels of investment on research and development activities along with introduction of advanced diagnostics procedure which will further bring immense opportunities for the growth of the cancer nanomedicine market in the above mentioned forecast period.

Low rate of adoption along with increasing side effects associated with the consumption of nanoparticles, stringent regulatory framework for approvals of drugs are acting as market restraints for the growth of the cancer nanomedicine market in the above mentioned forecast period.

According to this report Global Cancer Nanomedicine Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Cancer Nanomedicine Market includes comprehensive information derived from depth study on Cancer Nanomedicine Industry historical and forecast market data. Global Cancer Nanomedicine Market Size To Expand moderately as the new developments in Cancer Nanomedicine and Impact of COVID19 over the forecast period 2020 to 2027.

To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @

Cancer Nanomedicine Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Cancer Nanomedicine Market report is helpful for strategists, marketers and senior management, And Key Players in Cancer Nanomedicine Industry.

Key Segmentation:

By Type (Inorganic Nanoparticles, Organic Nanoparticles)

By Agent Type (Diagnostic Agents, Therapeutic Agents, Drug Delivery Agents)

By Mechanism (Targeting Tumor Cells, Nanocarrier Drug Complex, Drug Release Systems)

By Cancer Type (Breast Cancer, Pancreatic Cancer, Brain Cancer, Lung Cancer, Others)

By Imaging Technique (Positron Emission Tomography, Single Photon Emitted Tomography, Magnetic Resonance Imaging (MRI))

By Phase (Research, Preclinical, Phase-I, Phase-I/II, Phase-II, Phase-III)

Leading Players operating in the Cancer Nanomedicine Market are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@

The Cancer Nanomedicine market report also entails the vigorous evaluation about the growth plot and all opportunities &risk related to of global Cancer Nanomedicine market during the forecast period. In addition, the report comprises the key events and most recent innovations in the industry together with the prospective trends technological progresses within the global Cancer Nanomedicine market that can impact its expansion graph. Entailing the pivotal data on the markets statistics and dynamics, the report will serve as a valued asset in term of decision-making and guidance for the businesses and companies already active within industry or looking forward to enter into it.

Global Cancer Nanomedicine Market Scope and Market Size

Cancer nanomedicine market is segmented on the basis of type, agent type, mechanism, cancer type, imaging technique, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, cancer nanomedicine market is segmented into inorganic nanoparticles, and organic nanoparticles. Inorganic nanoparticles have been further segmented into synthesis of gold nanoparticle. Organic nanoparticles have been further segmented into polymeric nanoparticle, and lipid organic nanoparticles.

On the basis of agent type, cancer nanomedicine market is segmented into diagnostic agents, therapeutic agents, and drug delivery agents. Diagnostic agents have been further segmented into cancer biomarkers, diagnostic device and nanoprobes, and quantum dots. Diagnostic device and nanoprobes have been further sub segmented into biosensors, and microarrays. Therapeutic agents have been further segmented into photodynamic therapy, and photo thermal therapy.

Based on mechanism, cancer nanomedicine market is segmented into targeting tumor cells, nanocarrier drug complex, and drug release systems. Targeting tumor cells have been further segmented into passive targeting, and active targeting. Nanocarrier drug complex have been further segmented into liposomes, dendrimers, micelles, and inorganic nanocarriers.

On the basis of cancer type, cancer nanomedicine market is segmented into breast cancer, pancreatic cancer, brain cancer, lung cancer, and others.

Based on imaging technique, cancer nanomedicine market is segmented into positron emission tomography, single photon emitted tomography, and magnetic resonance imaging (MRI).

Cancer nanomedicine market has also been segmented based on the phase into research, preclinical, phase-I, phase-I/II, phase-II, and phase-III.

Geographically, the following regions together with the listed national/local markets are fully investigated:

For More Information or Query or Customization before Buying, Visit @

Reason to Buy

Access Full Report Directly @

Also, Research Report Examines:

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Cancer Nanomedicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product

Competition by Company: Here, the competition in the Worldwide Cancer Nanomedicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Cancer Nanomedicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Cancer Nanomedicine Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Cancer Nanomedicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Cancer Nanomedicine Market.

Market Forecast:Here, the report offers a complete forecast of the global Cancer Nanomedicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Browse Complete Report Details @

Its vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (, who will guarantee you to get a report that suits your necessities.

Our Others Reports:

Online Testing Software Market Trends, Size, Growth Insight, Industry Share, Emerging Technologies by ProProfs, QuizWorks, ExamSoft, EDBASE, Testment

Health Surveillance Systems Market Size, Trends, Future Growth, Latest Technology, Innovation With Competitive Analysis by Top Players-Avigilon, Schneider Electric, Cisco, Tyco Integrated Security, Nedap N.V., ADT

Hyperhidrosis Treatment Market Size, Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by COVID-19 Impact Analysis 2027

Head Mirror Market Analysis with Top Trends, Size, Share, Leading Companies, Key Regions, Segments, Mergers and Foreseen By DBMR Till 2027

About Data Bridge Market Research, Private Ltd

Data Bridge Market ResearchPvtLtdis a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

We provide a variety of services such as market verifiedindustry reports, technology trend analysis, Formative market research,strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

Contact Us

US: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475


This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Read more here:
Cancer Nanomedicine Market to Build Excessive Revenue at Healthy Growth rate at 12.50% up to 2027 -


Page 11234..10..»

2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick